These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38593230)

  • 1. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
    Fischer-Riepe L; Kailayangiri S; Zimmermann K; Pfeifer R; Aigner M; Altvater B; Kretschmann S; Völkl S; Hartley J; Dreger C; Petry K; Bosio A; von Döllen A; Hartmann W; Lode H; Görlich D; Mackensen A; Jungblut M; Schambach A; Abken H; Rossig C
    Clin Cancer Res; 2024 Aug; 30(16):3564-3577. PubMed ID: 38593230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
    Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
    Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma.
    Pascual-Pasto G; McIntyre B; Hines MG; Giudice AM; Garcia-Gerique L; Hoffmann J; Mishra P; Matlaga S; Lombardi S; Shraim R; Schürch PM; Yarmarkovich M; Hofmann TJ; Alikarami F; Martinez D; Tsang M; Gil-de-Gómez L; Spear TT; Bernt KM; Wolpaw AJ; Dimitrov DS; Li W; Bosse KR
    Nat Commun; 2024 Aug; 15(1):7141. PubMed ID: 39164224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner.
    Hull CM; Larcombe-Young D; Mazza R; George M; Davies DM; Schurich A; Maher J
    Mol Ther; 2024 Jul; 32(7):2373-2392. PubMed ID: 38745414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.
    Wu H; Zhang G; Liu Z; Liu W; Wang X; Zhao Y
    Cytotherapy; 2024 Nov; 26(11):1308-1319. PubMed ID: 38904586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
    Ciccone R; Quintarelli C; Camera A; Pezzella M; Caruso S; Manni S; Ottaviani A; Guercio M; Del Bufalo F; Quadraccia MC; Orlando D; Di Cecca S; Sinibaldi M; Aurigemma M; Iaffaldano L; Sarcinelli A; D'Amore ML; Ceccarelli M; Nazio F; Marabitti V; Giorda E; Pezzullo M; De Stefanis C; Carai A; Rossi S; Alaggio R; Del Baldo G; Becilli M; Mastronuzzi A; De Angelis B; Locatelli F
    Clin Cancer Res; 2024 Jun; 30(11):2545-2557. PubMed ID: 38551501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.
    Moghimi B; Muthugounder S; Jambon S; Tibbetts R; Hung L; Bassiri H; Hogarty MD; Barrett DM; Shimada H; Asgharzadeh S
    Nat Commun; 2021 Jan; 12(1):511. PubMed ID: 33479234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.
    Altvater B; Kailayangiri S; Spurny C; Flügge M; Meltzer J; Greune L; Urban K; Schwöppe C; Brand C; Schliemann C; Hintelmann H; Harrach S; Hartmann W; Abken H; Kuehle J; Schambach A; Görlich D; Berdel WE; Rossig C
    Cancer Gene Ther; 2023 Oct; 30(10):1355-1368. PubMed ID: 37391502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
    Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
    Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD
    Glienke W; Dragon AC; Zimmermann K; Martyniszyn-Eiben A; Mertens M; Abken H; Rossig C; Altvater B; Aleksandrova K; Arseniev L; Kloth C; Stamopoulou A; Moritz T; Lode HN; Siebert N; Blasczyk R; Goudeva L; Schambach A; Köhl U; Eiz-Vesper B; Esser R
    Front Immunol; 2022; 13():839783. PubMed ID: 35401506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
    Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
    J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
    Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
    BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
    Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
    Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
    Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.
    Gargett T; Ebert LM; Truong NTH; Kollis PM; Sedivakova K; Yu W; Yeo ECF; Wittwer NL; Gliddon BL; Tea MN; Ormsby R; Poonnoose S; Nowicki J; Vittorio O; Ziegler DS; Pitson SM; Brown MP
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
    Gargett T; Truong NTH; Gardam B; Yu W; Ebert LM; Johnson A; Yeo ECF; Wittwer NL; Tapia Rico G; Logan J; Sivaloganathan P; Collis M; Ruszkiewicz A; Brown MP
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.